サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1791751

ヌクレオチドの世界市場

Nucleotide

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
ヌクレオチドの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヌクレオチドの世界市場は2030年までに14億米ドルに達する見込み

2024年に9億7,690万米ドルと推定されるヌクレオチドの世界市場は、分析期間2024-2030年にCAGR 6.4%で成長し、2030年には14億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるデオキシヌクレオチドは、CAGR 7.8%を記録し、分析期間終了時には6億8,110万米ドルに達すると予測されています。RNA合成用ヌクレオチドセグメントの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は2億5,680万米ドルと推定、中国はCAGR6.1％で成長予測

米国のヌクレオチド市場は、2024年に2億5,680万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.1%として、2030年までに2億2,640万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.1%と5.2%と予測されています。欧州では、ドイツがCAGR 4.9%で成長すると予測されています。

世界のヌクレオチド市場- 主要動向と促進要因まとめ

なぜヌクレオチドは栄養、医薬品、バイオテクノロジーにおいて戦略的重要性を増しているのか？

ヌクレオチド-DNAとRNAの構成要素となる有機分子-は、様々な産業で急速に用途が拡大しており、基本的な生化学的成分から高価値の機能性成分へと変貌を遂げています。伝統的に、ヌクレオチドは細胞代謝、遺伝情報保存、エネルギー伝達（ATPなど）に不可欠な役割を果たすことで知られてきたが、現在では乳児栄養、動物飼料から医薬品、バイオテクノロジーに至るまで、幅広い分野で需要が高まっています。ヒトの栄養分野では、免疫サポートや胃腸の開発など、母乳に見られる機能的な利点を模倣するために、乳児用調製粉乳にヌクレオチドを添加するケースが増えています。動物の健康分野では、家畜飼料にヌクレオチドを添加することにより、腸の健康、成長性能、耐病性が改善されます。一方、製薬業界では、ヌクレオチドは抗ウイルス剤や抗がん剤の合成において前駆体や中間体として使用されています。遺伝子研究、診断、治療、特にPCRキット、mRNA合成、オリゴヌクレオチドベースの治療におけるヌクレオチドの役割は、COVID-19以降、新たな勢いを増しています。バイオテクノロジーとライフサイエンス産業が急速に拡大する中、ヌクレオチドは遺伝子治療、ワクチン開発、次世代シーケンサー（NGS）などの高度なアプリケーションの基礎原料になりつつあります。これらの最終用途領域が進化を続ける中、ヌクレオチドは健康、科学、イノベーションの交差点に位置づけられ、その市場価値は汎用化学品から戦略的バイオサイエンス投入物へとシフトしています。

技術の進歩とプロセスの最適化は、どのように製品の進化を促しているのか？

発酵技術、酵素合成、バイオプロセス工学の進歩は、ヌクレオチドの生産方法を再定義し、収率、純度、スケーラビリティを向上させ、急増する市場需要に応えています。酵母やその他の天然源からの伝統的な抽出が依然として一般的である一方で、現代の工業プロセスは、より高い効率性と持続可能性を実現するために、微生物発酵や酵素的バイオコンバージョンが好まれるようになっています。これらの方法は、生産コストを削減するだけでなく、医薬品や栄養剤の用途で重要なヌクレオチドの組成や濃度を正確に制御することを可能にします。メーカーはまた、注射剤や治療用製品における超高純度、GMP準拠のヌクレオチドに対するニーズの高まりに対応するため、下流の精製・結晶化技術にも投資しています。さらに、カスタマイズが重要な差別化要因になりつつあり、乳児用栄養剤、スポーツサプリメント、機能性食品などでは、特定の健康機能に合わせてテーラーメイドのヌクレオチドブレンドが処方されています。バイオインフォマティクスと合成生物学の台頭は、ヌクレオチドアナログ合成のための新しい経路を解き放ち、医薬品開発と遺伝子工学に大きな可能性をもたらしています。自動化、リアルタイムのプロセスモニタリング、データ主導の最適化が生産ラインにますます組み込まれるようになり、バッチの一貫性、規制遵守、環境の持続可能性が強化されています。このような技術革新により、サプライヤーはバリューチェーンを向上させ、バルクのヌクレオチドだけでなく、次世代ヘルスケア製品や栄養製品に迅速に統合できる、応用可能で機能強化された変異体を提供できるようになっています。

健康第一の世界経済において、ヌクレオチドの業界を超えた需要を促進しているものは何か？

免疫健康、疾病予防、バイオテクノロジー主導の技術革新に対する世界の関心の高まりは、ヌクレオチドの対応可能な市場を大幅に拡大しています。消費者栄養分野では、乳幼児期の発育と免疫に対する意識の高まりが、ヌクレオチドブレンドを含む強化乳児用調製粉乳の需要を牽引しています。同様に、免疫サポートや疲労回復を促進するサプリメントを求める成人が、食品や栄養補助食品ブランドに機能性製品ポートフォリオにヌクレオチドを含めるよう働きかけています。畜産業における抗生物質離れが、ヌクレオチドを家畜のパフォーマンスや耐病性を向上させるための貴重な代替物、特に家禽、養豚、水産養殖分野での代替物にしています。バイオテクノロジー分野では、PCR試薬、RNAベースの医薬品、診断ツールの需要が爆発的に伸びているため、ヌクレオチドは研究所や製薬メーカーにとって不可欠なものとなっています。COVID-19パンデミックはこの動向の起爆剤となり、迅速反応ワクチン開発と診断検査製造におけるヌクレオチドビルディングブロックの戦略的役割を強化しました。医薬品製造では、ヌクレオチドが合成医薬品原薬、特に抗ウイルス薬やがん治療薬の出発原料として使用されるケースが増えています。さらに、CRISPR技術、遺伝子編集、合成ワクチンにおける新たな使用事例が、新たな商業的道を開きつつあります。世界中のヘルスケアシステムが精密医療、免疫回復力、早期介入に重点を置く中、ヌクレオチドは治療戦略や予防医療製品に不可欠なものとなりつつあります。このような業界横断的な需要は、消費者の健康意識、農業の変革、生物医学の革新の収束を反映しており、これらはすべて、世界のバイオエコノミーにおけるヌクレオチドの役割が強固で拡大することを示しています。

ヌクレオチドの世界市場成長の原動力は？

ヌクレオチド市場の成長は、技術革新、最終用途の進化、規制当局の支援、消費者や産業界の優先事項のシフトに関連するいくつかの要因によって牽引されています。第一に、乳幼児栄養、機能性食品、動物飼料への応用拡大により、免疫、消化、健康全般をサポートするヌクレオチド強化製品への一貫した需要が生まれています。第二に、医薬品合成、ワクチン開発、遺伝子治療におけるバイオ医薬品業界のヌクレオチドへの依存度の高まりが、特に世界の感染症対策に伴い、市場の需要を大幅に押し上げています。第三に、バイオテクノロジーと遺伝子工学の進歩により、ヌクレオチドは原材料から診断薬、mRNA治療薬、オリゴヌクレオチド医薬品、DNAシーケンシング技術に不可欠な構成要素へと昇華しています。第四に、世界中の規制当局が、食品、飼料、医薬製剤にヌクレオチドを含めることを承認するようになっており、製品の正当性を高め、商業的採用を加速しています。第5に、製造業者は環境とコスト効率の目標に沿いながら生産物の品質を向上させる、環境に優しく拡張性のある生産技術に投資しています。第六に、抗生物質を使用しない家畜生産を目指す動きが、天然の成長促進剤や免疫調整剤としてのヌクレオチドへの需要を刺激しています。さらに、栄養補助食品におけるeコマースの成長とD2C流通は、地域と消費者セグメントを越えて製品リーチを拡大しています。これらの要因が相まって、ヌクレオチド市場は多部門にわたる持続的な成長を推進し、ライフサイエンス、栄養、バイオ加工業界における高価値セグメントとして確固たる地位を築いています。

セグメント

製品（デオキシヌクレオチド、RNA合成用ヌクレオチド、ジデオキシヌクレオチド、標識ヌクレオチド）、技術（TaqMan対立遺伝子識別技術、パイロシーケンスによるSNP技術、ジーンチップ＆マイクロアレイ技術、その他の技術）、用途（診断研究用途、医薬品用途、飲食品添加物用途、動物飼料添加物用途、その他の用途）

調査対象企業の例

  • Agilent Technologies
  • Ajinomoto Co., Inc.
  • ATTO-TEC GmbH
  • Bioline GmbH
  • Biomatik
  • Bioneer Corporation
  • CJ CheilJedang Corp.
  • Cytiva（formerly part of GE Healthcare）
  • Daesang Corporation
  • Danaher Corporation
  • Eton Bioscience
  • Eurofins Scientific
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH
  • LGC Biosearch Technologies
  • Merck KGaA
  • Revvity（formerly PerkinElmer）
  • Star Lake Bioscience
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32384

Global Nucleotide Market to Reach US$1.4 Billion by 2030

The global market for Nucleotide estimated at US$976.9 Million in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Deoxy Nucleotides, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$681.1 Million by the end of the analysis period. Growth in the Nucleotides for RNA Synthesis segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$256.8 Million While China is Forecast to Grow at 6.1% CAGR

The Nucleotide market in the U.S. is estimated at US$256.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$226.4 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.1% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Nucleotide Market - Key Trends & Drivers Summarized

Why Are Nucleotides Gaining Strategic Importance Across Nutrition, Pharmaceuticals, and Biotech?

Nucleotides-organic molecules that serve as the building blocks of DNA and RNA-are finding rapidly expanding applications across a variety of industries, transforming them from basic biochemical components into high-value functional ingredients. Traditionally known for their essential role in cellular metabolism, genetic information storage, and energy transfer (e.g., ATP), nucleotides are now in high demand in sectors ranging from infant nutrition and animal feed to pharmaceuticals and biotechnology. In human nutrition, nucleotides are increasingly added to infant formula to mimic the functional benefits found in breast milk, such as enhanced immune support and gastrointestinal development. In animal health, nucleotide supplementation in livestock feed improves gut health, growth performance, and disease resistance-especially in antibiotic-free production systems. Meanwhile, in the pharmaceutical industry, nucleotides are used as precursors or intermediates in the synthesis of antiviral and anticancer drugs. Their role in genetic research, diagnostics, and therapeutics, particularly in PCR kits, mRNA synthesis, and oligonucleotide-based treatments, has gained new momentum post-COVID-19. With biotech and life sciences industries expanding rapidly, nucleotides are becoming a foundational raw material in advanced applications such as gene therapy, vaccine development, and next-generation sequencing (NGS). As these end-use domains continue to evolve, nucleotides are positioned at the intersection of health, science, and innovation-shifting their market value from commodity chemicals to strategic bioscience inputs.

How Are Technological Advancements and Process Optimization Driving Product Evolution?

Advancements in fermentation technology, enzymatic synthesis, and bioprocess engineering are redefining how nucleotides are produced, improving yield, purity, and scalability to meet surging market demand. While traditional extraction from yeast or other natural sources remains common, modern industrial processes now favor microbial fermentation and enzymatic bioconversion for higher efficiency and sustainability. These methods not only reduce production costs but also allow for precise control over nucleotide composition and concentration-critical in pharmaceutical and nutritional applications. Manufacturers are also investing in downstream purification and crystallization technologies to meet the growing need for ultra-pure, GMP-compliant nucleotides in injectable and therapeutic products. Further, customization is becoming a key differentiator, with tailored nucleotide blends being formulated for specific health functions in infant nutrition, sports supplements, and functional foods. The rise of bioinformatics and synthetic biology is also unlocking novel pathways for nucleotide analog synthesis, which holds significant promise in drug development and genetic engineering. Automation, real-time process monitoring, and data-driven optimization are increasingly being integrated into production lines, enhancing batch consistency, regulatory compliance, and environmental sustainability. These innovations are enabling suppliers to move up the value chain-offering not just bulk nucleotides, but application-ready, functionally enhanced variants that can be quickly integrated into next-gen healthcare and nutrition products.

What’s Fueling Cross-Industry Demand for Nucleotides in a Health-First Global Economy?

The growing global emphasis on immune health, disease prevention, and biotechnology-driven innovation is significantly expanding the addressable market for nucleotides. In the consumer nutrition sector, increased awareness of early-life development and immunity is driving demand for fortified infant formulas containing nucleotide blends. Similarly, adults seeking immune-supporting or recovery-enhancing supplements are pushing food and nutraceutical brands to include nucleotides in functional product portfolios. The shift away from antibiotics in animal agriculture has made nucleotides a valuable alternative for improving livestock performance and disease resistance-especially in poultry, swine, and aquaculture sectors. In biotechnology, the explosion in demand for PCR reagents, RNA-based drugs, and diagnostic tools has made nucleotides indispensable to research labs and pharmaceutical manufacturers alike. The COVID-19 pandemic acted as a catalyst for this trend, reinforcing the strategic role of nucleotide building blocks in rapid-response vaccine development and diagnostic test production. In pharmaceutical manufacturing, nucleotides are increasingly used as starting materials for synthetic drug APIs, especially antivirals and oncology drugs. Additionally, emerging use cases in CRISPR technologies, genetic editing, and synthetic vaccines are opening new commercial pathways. As healthcare systems worldwide focus on precision medicine, immune resilience, and early intervention, nucleotides are becoming integral to therapeutic strategies and preventive health products. This cross-industry demand reflects a convergence of consumer health consciousness, agricultural transformation, and biomedical innovation-all pointing toward a robust and expanding role for nucleotides in the global bioeconomy.

What’s Driving the Growth of the Global Nucleotide Market?

The growth in the nucleotide market is driven by several factors tied to technological innovation, evolving end-use applications, regulatory support, and shifts in consumer and industrial priorities. First, expanding applications in infant nutrition, functional foods, and animal feed are creating consistent demand for nucleotide-fortified products that support immunity, digestion, and overall wellness. Second, the biopharmaceutical industry's rising reliance on nucleotides for drug synthesis, vaccine development, and gene therapy is significantly boosting market demand-particularly in the wake of global infectious disease preparedness initiatives. Third, advancements in biotechnology and genetic engineering have elevated nucleotides from raw materials to essential building blocks in diagnostics, mRNA therapeutics, oligonucleotide drugs, and DNA sequencing technologies. Fourth, regulatory authorities across the globe are increasingly approving nucleotide inclusion in food, feed, and pharma formulations, enhancing the product's legitimacy and accelerating commercial adoption. Fifth, manufacturers are investing in green, scalable production technologies that improve output quality while aligning with environmental and cost-efficiency goals. Sixth, the move toward antibiotic-free livestock production is stimulating demand for nucleotides as a natural growth enhancer and immune modulator. Furthermore, e-commerce growth and D2C distribution in nutraceuticals are expanding product reach across geographies and consumer segments. Together, these factors are driving sustained, multi-sectoral growth in the nucleotide market, firmly positioning it as a high-value segment within the life sciences, nutrition, and bioprocessing industries.

SCOPE OF STUDY:

The report analyzes the Nucleotide market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides, Labelled Nucleotides); Technology (TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology, Other Technologies); Application (Diagnostics Research Application, Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Agilent Technologies
  • Ajinomoto Co., Inc.
  • ATTO-TEC GmbH
  • Bioline GmbH
  • Biomatik
  • Bioneer Corporation
  • CJ CheilJedang Corp.
  • Cytiva (formerly part of GE Healthcare)
  • Daesang Corporation
  • Danaher Corporation
  • Eton Bioscience
  • Eurofins Scientific
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH
  • LGC Biosearch Technologies
  • Merck KGaA
  • Revvity (formerly PerkinElmer)
  • Star Lake Bioscience
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Nucleotide - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Functional Ingredients in Health and Nutrition Throws the Spotlight on Nucleotide Applications
    • Expansion of Infant Formula Fortification Strengthens the Business Case for Nutritional-Grade Nucleotides
    • Rising Use of Nucleotides in Animal Feed Propels Growth in Antibiotic-Free Livestock Production
    • Here's How Biopharmaceutical Advancements Are Expanding the Addressable Market Opportunity for Pharmaceutical-Grade Nucleotides
    • Increased Adoption in mRNA and Gene Therapy Manufacturing Drives Demand for High-Purity Nucleotide Inputs
    • Surging Investment in Molecular Diagnostics and PCR Technologies Accelerates Nucleotide Consumption in Life Sciences
    • Evolving Role of Nucleotides in Immunity and Gut Health Supplements Spurs Innovation in Nutraceutical Applications
    • Biotech-Driven Production Methods and Fermentation Technology Strengthen Cost-Efficiency and Product Scalability
    • Supply Chain Diversification and Regional Manufacturing Capabilities Expand Access in Emerging Markets
    • Rising Preference for Clean-Label, Allergen-Free, and Sustainable Ingredients Fuels Demand for Bio-Based Nucleotides
    • Integration into Functional Beverages and Sports Nutrition Broadens Consumer-Centric Product Development
    • Next-Generation Sequencing (NGS) and Synthetic Biology Innovations Generate Long-Term Demand for Specialty Nucleotides
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nucleotide Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nucleotide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Nucleotide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Deoxy Nucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Deoxy Nucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Nucleotides for RNA Synthesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Nucleotides for RNA Synthesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Dideoxynucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Dideoxynucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Labelled Nucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Labelled Nucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Pharmaceuticals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Pharmaceuticals Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Food & Beverage Additives Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Food & Beverage Additives Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Animal Feed Additives Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Animal Feed Additives Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostics Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Diagnostics Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for TaqMan Allelic Discrimination Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for TaqMan Allelic Discrimination Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for SNP By Pyrosequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for SNP By Pyrosequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Gene Chips & Microarrays Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Gene Chips & Microarrays Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Nucleotide by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Nucleotide by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Nucleotide Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Nucleotide by Product - Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Nucleotide by Product - Percentage Breakdown of Value Sales for Deoxy Nucleotides, Nucleotides for RNA Synthesis, Dideoxynucleotides and Labelled Nucleotides for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Nucleotide by Application - Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Nucleotide by Application - Percentage Breakdown of Value Sales for Pharmaceuticals Application, Food & Beverage Additives Application, Animal Feed Additives Application, Other Applications and Diagnostics Research Application for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Nucleotide by Technology - TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Nucleotide by Technology - Percentage Breakdown of Value Sales for TaqMan Allelic Discrimination Technology, SNP By Pyrosequencing Technology, Gene Chips & Microarrays Technology and Other Technologies for the Years 2025 & 2030

IV. COMPETITION